- Home
- ARHS vs MESO Comparison
ARHS vs MESO Comparison
Compare ARHS & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARHS
- MESO
- Stock Information
- Founded
- ARHS 1986
- MESO 2004
- Country
- ARHS United States
- MESO Australia
- Employees
- ARHS N/A
- MESO N/A
- Industry
- ARHS Other Specialty Stores
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARHS Consumer Discretionary
- MESO Health Care
- Exchange
- ARHS Nasdaq
- MESO Nasdaq
- Market Cap
- ARHS 1.5B
- MESO 1.3B
- IPO Year
- ARHS 2021
- MESO N/A
- Fundamental
- Price
- ARHS $10.34
- MESO $18.05
- Analyst Decision
- ARHS Buy
- MESO Buy
- Analyst Count
- ARHS 13
- MESO 2
- Target Price
- ARHS $11.71
- MESO $24.00
- AVG Volume (30 Days)
- ARHS 1.8M
- MESO 285.6K
- Earning Date
- ARHS 11-06-2025
- MESO 08-28-2025
- Dividend Yield
- ARHS N/A
- MESO N/A
- EPS Growth
- ARHS N/A
- MESO N/A
- EPS
- ARHS 0.50
- MESO N/A
- Revenue
- ARHS $1,335,951,000.00
- MESO $17,198,000.00
- Revenue This Year
- ARHS $8.57
- MESO $288.50
- Revenue Next Year
- ARHS $7.03
- MESO $167.17
- P/E Ratio
- ARHS $20.59
- MESO N/A
- Revenue Growth
- ARHS 4.76
- MESO 191.39
- 52 Week Low
- ARHS $6.61
- MESO $7.09
- 52 Week High
- ARHS $13.02
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- ARHS 40.16
- MESO 63.51
- Support Level
- ARHS $10.46
- MESO $17.10
- Resistance Level
- ARHS $11.20
- MESO $18.91
- Average True Range (ATR)
- ARHS 0.42
- MESO 0.54
- MACD
- ARHS -0.07
- MESO 0.18
- Stochastic Oscillator
- ARHS 11.40
- MESO 75.65
About ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.